【FDA批准首个用于诊断阿尔茨海默氏症的血液检测技术】美国食品药品监督管理局周五表示,该机构已批准Fujirebio Diagnostics公司的血液检测技术“Lumipulse”用于诊断阿尔茨海默病,成为首个获批的阿尔茨海默氏症血液检测设备。血液检测可以加快疾病的诊断,并使更多的人更容易获得治疗方法。检测阿尔茨海默氏症的其他方法包括脊髓穿刺,这需要侵入性穿刺来收集脊髓液,或者昂贵的PET脑部扫描,健康保险公司可能不会提供报销。

金融界
17 May
美国食品药品监督管理局周五表示,该机构已批准Fujirebio Diagnostics公司的血液检测技术“Lumipulse”用于诊断阿尔茨海默病,成为首个获批的阿尔茨海默氏症血液检测设备。血液检测可以加快疾病的诊断,并使更多的人更容易获得治疗方法。检测阿尔茨海默氏症的其他方法包括脊髓穿刺,这需要侵入性穿刺来收集脊髓液,或者昂贵的PET脑部扫描,健康保险公司可能不会提供报销。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10